Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

1.

Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy.

Strauss WL, Layton ME, Dager SR.

Am J Psychiatry. 1998 Mar;155(3):380-4.

PMID:
9501749
[PubMed - indexed for MEDLINE]
2.

19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.

Strauss WL, Layton ME, Hayes CE, Dager SR.

Am J Psychiatry. 1997 Apr;154(4):516-22.

PMID:
9090339
[PubMed - indexed for MEDLINE]
3.

Characterization of human brain pharmacokinetics using a two-compartment model.

Strauss WL, Layton ME, Dager SR.

Biol Psychiatry. 1999 May 15;45(10):1384-8.

PMID:
10349045
[PubMed - indexed for MEDLINE]
4.

Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.

Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR.

Am J Psychiatry. 2002 May;159(5):755-60.

PMID:
11986128
[PubMed - indexed for MEDLINE]
5.

Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.

Bolo NR, Hodé Y, Nédélec JF, Lainé E, Wagner G, Macher JP.

Neuropsychopharmacology. 2000 Oct;23(4):428-38.

PMID:
10989270
[PubMed - indexed for MEDLINE]
Free Article
6.

Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo.

Bolo NR, Hodé Y, Macher JP.

MAGMA. 2004 May;16(6):268-76. Epub 2004 Mar 23.

PMID:
15042463
[PubMed - indexed for MEDLINE]
7.

Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy.

Christensen JD, Yurgelun-Todd DA, Babb SM, Gruber SA, Cohen BM, Renshaw PF.

Brain Res. 1999 Jul 10;834(1-2):1-5.

PMID:
10407087
[PubMed - indexed for MEDLINE]
8.

Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.

Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Apr;69(4):194-200.

PMID:
11309547
[PubMed - indexed for MEDLINE]
9.

Fluorinated blood substitute retention in the rat measured by fluorine-19 magnetic resonance imaging.

Meyer KL, Carvlin MJ, Mukherji B, Sloviter HA, Joseph PM.

Invest Radiol. 1992 Aug;27(8):620-7.

PMID:
1428740
[PubMed - indexed for MEDLINE]
10.

A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.

Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P.

Clin Cancer Res. 2003 Nov 1;9(14):5101-12. Review.

PMID:
14613987
[PubMed - indexed for MEDLINE]
Free Article
11.

In vivo 19F-NMR study of isoflurane elimination from brain.

Wyrwicz AM, Conboy CB, Ryback KR, Nichols BG, Eisele P.

Biochim Biophys Acta. 1987 Jan 19;927(1):86-91.

PMID:
3790622
[PubMed - indexed for MEDLINE]
12.

Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.

Schneider E, Bolo NR, Frederick B, Wilkinson S, Hirashima F, Nassar L, Lyoo IK, Koch P, Jones S, Hwang J, Sung Y, Villafuerte RA, Maier G, Hsu R, Hashoian R, Renshaw PF.

J Clin Pharm Ther. 2006 Jun;31(3):261-73.

PMID:
16789992
[PubMed - indexed for MEDLINE]
13.

Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers.

Jufer RA, Wstadik A, Walsh SL, Levine BS, Cone EJ.

J Anal Toxicol. 2000 Oct;24(7):467-77.

PMID:
11043648
[PubMed - indexed for MEDLINE]
Free Article
14.

Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy.

Durst P, Schuff N, Crocq MA, Mokrani MC, Macher JP.

Psychiatry Res. 1990 Dec;35(2):107-14.

PMID:
2100803
[PubMed - indexed for MEDLINE]
15.

Elimination kinetics and symptomatology of diazepam withdrawal in abusers.

Rhodes PJ, Rhodes RS, McCurdy HH.

J Toxicol Clin Toxicol. 1984;22(4):371-85.

PMID:
6441848
[PubMed - indexed for MEDLINE]
16.

Fluorine-19 nuclear magnetic resonance imaging and spectroscopy of sevoflurane uptake, distribution, and elimination in rat brain.

Xu Y, Tang P, Zhang W, Firestone L, Winter PM.

Anesthesiology. 1995 Oct;83(4):766-74.

PMID:
7574056
[PubMed - indexed for MEDLINE]
Free Article
17.

Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.

Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ.

Clin Pharmacol Ther. 2004 Apr;75(4):331-41.

PMID:
15060511
[PubMed - indexed for MEDLINE]
18.

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

Fleishaker JC, Hulst LK.

Eur J Clin Pharmacol. 1994;46(1):35-9.

PMID:
8005185
[PubMed - indexed for MEDLINE]
19.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
20.

Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study.

Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF.

Am J Psychiatry. 2000 Sep;157(9):1506-8.

PMID:
10964871
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk